EGFR and non-small cell lung carcinoma: To this aim, our initial approach involved chronic adaptation of EGFR del746‐750 PC‐9 NSCLC cells to increasing doses of Gefitinib over a 6‐month duration (Ogino et al, 2007; Rho et al, 2009).